Breast Cancer Canada, a national charity dedicated to advancing breast cancer research and care, is excited to announce ...

The rates of life-threatening breast cancer are spiking among women of all ages, with a significant increase in those under ...

Patients with ER-positive/HER2-negative metastatic breast cancer who received elacestrant experienced a significant reduction ...

Median overall survival (OS) to date of 13.4 months for Phase 2 patients treated with the Phase 3 formulation (15.6 months for those treated ...

The event will be webcast live and can be accessed by visiting the Investors section of ALX Oncology's website at ...

A professor at the University of Illinois is pioneering cancer research that could curb tumor growth. Erik Nelson is an ...

ADELA, an international phase III study being conducted across multiple countries, combines elacestrant with everolimus to ...

Praise Is The Cure, a faith-based breast cancer awareness program for Black women, also reaches out to the men who have been ...

AstraZeneca and MSD's PARP inhibitor Lynparza has improved long-term survival when given as adjuvant therapy for early breast ...

AstraZeneca (AZN) and Merck (MRK) reported positive long-term survival data for their drug Lynparza in the treatment of ...

Bio-Techne Corp. TECH has launched a highly sensitive ESR1 mutation monitoring assay through its Asuragen brand. ESR1 gene mutations are known to be linked to hormone receptor-positive (HR+) ...

Arvinas, Pfizer announce initial phase 1b data from the TACTIVE-U sub-study of vepdegestrant in combo with abemaciclib at 2024 SABC symposium: New Haven, Connecticut Thursday, Dec ...